



Step Pharma to participate at upcoming scientific and business conferences

St. Genis-Pouilly, France, xx April 2023 - Step Pharma, the world leader in CTPS1 inhibition for the targeted treatment of cancer, today announces that members of its management team will be participating at a number of conferences in May and June 2023.

By targeting CTPS1, an enzyme that catalyses a rate-limiting step in pyrimidine synthesis, Step Pharma has unlocked the ability to selectively inhibit the *de novo* pyrimidine synthesis pathway, enabling a highly selective treatment of cancer.

[23rd BioEquity Europe](#), Dublin, Ireland, 15-16 May & 22-23 May Digital Partnering

- In person corporate presentation by Andrew Parker, CEO at 1.28pm on 5 May

[2023 ASCO Annual Meeting](#), Chicago, IL, US, 2-6 June

- **Poster presentation:** [A phase 1/2 study of STP938, a first-in-class inhibitor of CTP synthase 1, in patients with relapsed/refractory B or T cell lymphoma.](#)

Authors: Manish Patel, Matthew Ahearne, Kim Linton, Christopher Fox, David Lewis, Maureen Higgins, Brian Schwartz, Philip Beer, Michael Tees

Session Title: Hematologic Malignancies - Lymphoma and Chronic Lymphocytic Leukemia

Session Date and Time: 6/5/2023, 8:00 AM-11:00 AM CST

Track: Hematological Malignancies

Subtrack: Non-Hodgkin Lymphoma

Clinical Trial Registration Number: [NCT05463263](#)

Abstract #TPS7591

Poster Bd #135b

[BIO International Convention Congress](#), Boston, MA, US, 5-8 June

[International Conference of Malignant Lymphoma](#), Lugano, Switzerland, 13-17 June

-Ends-

About Step Pharma

Step Pharma's goal is to bring about a step change in how cancer is treated with targeted therapies that kill cancer cells and leave healthy cells unharmed. The Company is the world leader in CTPS1 inhibition, a new approach with the potential to yield highly selective, safe and effective treatments for both blood cancers and solid tumours.

The Company's lead asset, STP938, has received both IND and CTA clearance to proceed into first in human trials in the US and UK for the treatment of T cell and B cell lymphomas. Clinical trials in lymphoma commenced in September 2022. STP938 has the potential to be



the backbone of a multitude of cancer therapies as well as a potent monotherapy for hard-to-treat blood cancers.

Step Pharma was founded in 2014 by Kurma Partners, the Imagine Institute and Sygnature Discovery, based on the scientific discoveries of Prof. Alain Fischer and Dr Sylvain Latour. Step Pharma is based in Saint-Genis-Pouilly, France, and is supported by a strong syndicate of investors led by Kurma Partners and including Bpifrance (Fonds Biothérapies Innovantes et Maladies Rares and InnoBio2 Fund), Pontifax, Hadean Ventures, Sunstone Life Science Ventures, Inserm Transfert Initiative, Idinvest, Sygnature Discovery and the Imagine Institute. More information on the company can be found at www.step-ph.com.

For more information please contact:

Step Pharma

Andrew Parker, Chief Executive Officer
contact@step-ph.com

Consilium Strategic Communications

Amber Fennell, Namrata Taak, Stella Lempidaki
Tel: +44 (0) 20 3709 5700
steppharma@consilium-comms.com